Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

HLA-A*11:01 (Monomer) protein (KRAS G12R)

Spezies: Human Wirt: HEK-293 Cells Recombinant > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
Produktnummer ABIN7454289
  • Target
    HLA-A*11:01
    Protein-Typ
    Recombinant
    Proteineigenschaft
    Monomer
    Spezies
    Human
    Quelle
    • 31
    • 6
    • 1
    HEK-293 Cells
    Aufreinigungstag / Konjugat
    KRAS G12R
    Verwendungszweck
    Human HLA-A*11:01 & B2M & KRAS G12R (VVVGARGVGK) Monomer Protein
    Sequenz
    Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGARGVGK peptide
    Spezifität
    Uni-Prot: AAV53343.1 (HLA-A*11:01), P61769 (B2M), VVVGARGVGK
    Produktmerkmale
    Recombinant Human HLA-A*11:01 & B2M & KRAS G12R (VVVGARGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGARGVGK peptide.
    Reinheit
    > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
    Sterilität
    0.22 μm filtered
    Endotoxin-Niveau
    Less than 1EU per μg by the LAL method.
  • Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Rekonstitution
    Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
    Buffer
    Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
    Lagerung
    -20 °C,-80 °C
    Informationen zur Lagerung
    -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Haltbarkeit
    12 months
  • Target
    HLA-A*11:01
    Hintergrund
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    Molekulargewicht
    50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Tris-Bis PAGE result.
Sie sind hier: